MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

155.12 +2.00 (+1.31%)
Official Closing Price Updated: 7:00 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,445,155
Open 153.48
Bid (Size) 155.15 (100)
Ask (Size) 157.20 (100)
Prev. Close 153.12
Today's Range 153.41 - 155.84
52wk Range 112.34 - 170.46
Shares Outstanding N/A
Dividend Yield 3.08%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal ↗
Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers. 
Via Benzinga
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network

Performance

YTD
+12.0%
+12.0%
1 Month
+2.9%
+2.9%
3 Month
+3.6%
+3.6%
6 Month
+11.5%
+11.5%
1 Year
+31.5%
+31.5%

More News

Read More
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
Via The Motley Fool
News headline image
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study ↗
Via Benzinga
News headline image
IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗
Via The Motley Fool
Topics ETFs
News headline image
VXUS Has Delivered Better Returns Than IEFA Over the Past 5 Years. Should It Be in Your Portfolio? ↗
Via The Motley Fool
Topics ETFs
News headline image
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗
Via MarketBeat
News headline image
IEFA: Why This Fund Is One of the Best International ETFs ↗
Via The Motley Fool
Topics ETFs
News headline image
Dry eye syndrome drugs Market Size, Industry Report By 2035 ↗
Via Talk Markets
Topics Economy
News headline image
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns. ↗
Via The Motley Fool
Topics ETFs
News headline image
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗
Via The Motley Fool
News headline image
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem ↗
Via The Motley Fool
Topics ETFs
News headline image
Pediatrics Medicine Market Size, Industry Report By 2035 ↗
Via Talk Markets
Topics Economy
News headline image
3 International ETFs for Investors Looking Beyond U.S. Stocks ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗
Via MarketBeat
Topics Credit Cards ETFs Economy
News headline image
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗
Via MarketBeat
News headline image
PTCT Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout ↗
Via Investor's Business Daily
News headline image
Incyte (INCY) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Novartis Dips As Generics Take A Bite Out Of Its First-Quarter Sales ↗
Via Investor's Business Daily
News headline image
Better Pharma Dividend Stock: Novartis vs. Merck ↗
Via The Motley Fool
Topics Intellectual Property

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 155.12
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 06/25/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story